Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wan Wang

Showing results (471-480 of 486) with videos related to

Pageof 49
Sort By:
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Cell Transplantation|May 13, 2014
Decellularization and recellularization technologies in tissue engineeringRu-Huei Fu, Yu-Chi Wang, Shih-Ping Liu, et al.
Journal of the National Cancer Institute|October 3, 2002
Randomized trial of breast self-examination in Shanghai: final resultsDavid B Thomas, Dao Li Gao, Roberta M Ray, et al.
Journal of Gastroenterology and Hepatology|January 25, 2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogSakura Kirino, Nobuharu Tamaki, Shun Kaneko, et al.
Cancers|October 12, 2019
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World PracticeWan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 27, 2017
Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolizationYutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Digestive Diseases (Basel, Switzerland)|August 4, 2021
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by TolvaptanLeona Osawa, Hiroyuki Nakanishi, Masayuki Kurosaki, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 25, 2005
[Randomized trial of breast self-examination in 266,064 women in Shanghai]Dao-li Gao, David B Thomas, Roberta M Ray, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 30, 2009
The novel lipopolysaccharide-binding protein CRISPLD2 is a critical serum protein to regulate endotoxin functionZhi-Qin Wang, Wen-Ming Xing, Hua-Hua Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III studyTaroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.
Pageof 49

Showing results (471-480 of 486) with videos related to

Sort By:
Pageof 49
Plos One|April 21, 2020
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinomaSakura Kirino, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Cell Transplantation|May 13, 2014
Decellularization and recellularization technologies in tissue engineeringRu-Huei Fu, Yu-Chi Wang, Shih-Ping Liu, et al.
Journal of the National Cancer Institute|October 3, 2002
Randomized trial of breast self-examination in Shanghai: final resultsDavid B Thomas, Dao Li Gao, Roberta M Ray, et al.
Journal of Gastroenterology and Hepatology|January 25, 2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogSakura Kirino, Nobuharu Tamaki, Shun Kaneko, et al.
Cancers|October 12, 2019
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World PracticeWan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 27, 2017
Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolizationYutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, et al.
Digestive Diseases (Basel, Switzerland)|August 4, 2021
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by TolvaptanLeona Osawa, Hiroyuki Nakanishi, Masayuki Kurosaki, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|August 25, 2005
[Randomized trial of breast self-examination in 266,064 women in Shanghai]Dao-li Gao, David B Thomas, Roberta M Ray, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 30, 2009
The novel lipopolysaccharide-binding protein CRISPLD2 is a critical serum protein to regulate endotoxin functionZhi-Qin Wang, Wen-Ming Xing, Hua-Hua Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III studyTaroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.
Pageof 49